Eris Biotech Analysis: $500K Raised
What is Eris Biotech?
Eris Biotech specializes in developing small-molecule inhibitors that target immune evasion in cancer. Their innovative approach does not rely on protein targets, allowing for broader patient eligibility. This technology aims to reawaken the immune system to effectively fight cancer, potentially transforming treatment outcomes for patients.
Employees
1-10
Founded
2023
Industry
HealthTech, Biotech
Product Features & Capabilities
- First-in-class small-molecule inhibitor for cancer treatment
- Orally administered drug for patient safety
- Non-protein target approach for wider applicability
- Immune system reactivation technology
- Proprietary methods to block immune evasion.
Use Cases
Treat cancer by blocking immune evasion; Enhance patient safety with oral medication; Expand treatment options for diverse patient populations; Activate immune response against tumors; Improve cancer treatment efficacy.
How much Eris Biotech raised
Pre-Seed - $500,000
March 8, 2024Lead Investor: Y Combinator
See something that needs updating? Suggest edits to this profile.